What is William Blair’s Estimate for TENX FY2024 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Analysts at William Blair raised their FY2024 EPS estimates for shares of Tenax Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. William Blair analyst M. Phipps now forecasts that the specialty pharmaceutical company will post earnings of ($0.60) per share for the year, up from their prior estimate of ($6.90). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. William Blair also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($0.14) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.93) EPS and FY2027 earnings at ($1.03) EPS.

A number of other equities research analysts have also recently commented on the stock. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. Guggenheim started coverage on shares of Tenax Therapeutics in a report on Monday, October 14th. They issued a “buy” rating and a $16.00 price target on the stock. StockNews.com started coverage on shares of Tenax Therapeutics in a report on Thursday, September 26th. They set a “sell” rating on the stock. Finally, Leerink Partners started coverage on shares of Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 target price on the stock. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Stock Down 0.8 %

NASDAQ:TENX opened at $4.83 on Monday. The firm’s 50 day moving average is $4.02 and its 200 day moving average is $3.70. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month high of $33.44.

Institutional Investors Weigh In On Tenax Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sphera Funds Management LTD. bought a new position in shares of Tenax Therapeutics in the third quarter worth $101,000. Stonepine Capital Management LLC bought a new position in shares of Tenax Therapeutics in the third quarter worth $173,000. Finally, Vestal Point Capital LP bought a new position in shares of Tenax Therapeutics in the third quarter worth $288,000. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.